WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®)
WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®)
WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®
WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®
News Brief: WEX Pharmaceuticals Inc. Announces Addition Of Intellectual Property For Its Novel Development And Use Of Tetrodotoxin (TTX) To Relieve Pain
VANCOUVER, BC, August 22, 2023 — WEX Pharmaceuticals Inc. (“WEX”, or the “Company”), a biopharmaceutical company based in Vancouver, Canada developing a non-opioid analgesic, Halneuron® (“tetrodotoxin” or “TTX”), today announced the publication of a recent patent application filed with the World the Intellectual Property Organization (WIPO) through the Patent Cooperation Treaty (“PCT”). The application, as published is directed to a novel injectable formulation of tetrodotoxin.
News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain
Vancouver, BC (March 21, 2023) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient in Korea has been enrolled in its multinational Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain (the “Clinical Trial”).
News Brief: WEX Pharmaceuticals Inc. Announces Management Changes
Vancouver, BC (February 8, 2023) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, is pleased to announce the following executive appointments, effective immediately. Mr. Walter Korz will assume the role of Chief Executive Officer (CEO) of the Company, and Mr. Abner Yong will assume the role of Chief Financial Officer.